Medical Publications

1. Sangal R. Rotating Intern’s Images of Practitioners of Five Medical Specialties. J. Med. Educ., 54:500-502, 1979.
2. Sangal R, Coyle G, Hoehn-Saric R. Chronic Anxiety and Social Adjustment. Comprehensive Psychiatry, 24:75-78, 1983.
3. Sangal R, Correa EI, DePaulo R. Depression and Anxiety Inventories, and the Dexamethasone Suppression Test. Biological Psychiatry, 19:1207-1213, 1984.
4. Sangal R, Dimitrijevic R. Neuroleptic Malignant Syndrome: Successful Treatment with Pancuronium. JAMA, 254:2795-2796, 1985. Translated into the French, Italian and Japanese editions.
5. Sangal RB, Thomas L, Mitler MM. The Maintenance of Wakefulness Test (MWT) and the Multiple Sleep Latency Test (MSLT) measure different abilities in patients with sleep disorders. Chest, 101:898-902, 1992.
6. Sangal RB, Thomas L, Mitler MM. Disorders of Excessive Sleepiness: Treatment Improves Ability to Stay Awake but Does Not Reduce Sleepiness. Chest, 102:699-703, 1992.
7. Sangal RB, Sangal JM. P300 Latency: Abnormal in Sleep Apnea with Somnolence and Idiopathic Hypersomnia, but Normal in Narcolepsy. Clinical Electroencephalography, 26:146-153, 1995.
8. Sangal JM, Sangal RB, Persky B. Abnormal Auditory P300 Topography in Attention Deficit Disorder predicts Poor Response to Pemoline. Clinical Electroencephalography, 26:204-213, 1995.
9. Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Children. Clinical Electroencephalography, 27:46-51, 1996.
10. Sangal RB, Sangal JM. Closed Head Injury Patients with Mild Cognitive Complaints without Neurological or Psychiatric Findings have abnormal Visual P300 Latencies. Biological Psychiatry, 39:305-307, 1996.
11. Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Adults. Clinical Electroencephalography, 27:145-150, 1996.
12. Sangal JM, Sangal RB, Persky B. Prolonged P300 Latency in Attention Deficit Hyperactivity Disorder predicts poor response to Imipramine. Clinical Electroencephalography, 27:191-201, 1996.
13. Sangal RB, Sangal JM. Obstructive Sleep Apnea and Abnormal P300 Latency Topography. Clinical Electroencephalography, 28:16-25, 1997.
14. Sangal RB, Semery J-P, Belisle CL. Computerized Scoring of Abnormal Human Sleep: A Validation. Clinical Electroencephalography, 28: 64-67, 1997.
15. Sangal RB, Sangal JM. Measurement of P300 and Sleep Characteristics in Patients with Hypersomnia: Do P300 Latencies, P300 Amplitudes and Multiple Sleep Latency and Maintenance of Wakefulness Tests measure different Factors? Clinical Electroencephalography, 28:179-184, 1997.
16. Sangal RB, Sangal JM. Abnormal Visual P300 Latency in Obstructive Sleep Apnea does not Change Acutely upon Treatment with CPAP. Sleep, 20:702-704, 1997.
17. Doghramji K, Mitler MM, Sangal RB, et al. A Normative Study of the Maintenance of Wakefulness Test (MWT). Electroencephalography and Clinical Neurophysiology, 103:554-562, 1997.
18. US Modafinil in Narcolepsy Multicenter Study Group (incl. Sangal RB., Sangal JM, Belisle C, et al.). Randomized Trial of Modafinil for the Treatment of Pathological Somnolence in Narcolepsy. Ann Neurol, 43:88-97, 1998.
19. Sangal RB, Sangal JM. P300 Latency and Age: A Quadratic Regression explains their Relationship from Age 5 to 85. Clinical Electroencephalography, 29:1-6, 1998.
20. Mitler MM, Walsleben J, Sangal RB, Hirshkowitz M. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalography and Clinical Neurophysiology, 107:33-38, 1998.
21. Sangal RB, Sangal JM, Belisle C. Longer Auditory and Visual P300 Latencies in Patients with Narcolepsy. Clinical Electroencephalography, 30:28-32, 1999.
22. Sangal RB, Sangal JM, Belisle C. Subjective and Objective Indices of Sleepiness (ESS and MWT) are not equally useful in patients with Sleep Apnea. Clin Electroencephalography, 30:73-75, 1999.
23. Sangal RB, Sangal JM, Belisle C. Visual P300 Latency Predicts Treatment Response to Modafinil in Patients with Narcolepsy. Clin Neurophysiology, 110:1041-1047, 1999.
24. Sangal RB Mitler MM, Sangal JM. Subjective Sleepiness Ratings (Epworth Sleepiness Scale) do not reflect the same Parameter of Sleepiness as Objective Sleepiness (Maintenance of Wakefulness Test) in patients with Narcolepsy. Clin Neurophysiology, 110:2131-2135, 1999.
25. Michelson D, Allen AJ, Busner C, Casat C, Dunn D, Kratochvil C., Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
26. Sangal RB, Sangal JM. What is a Significant Response in Drug Studies of Attention Deficit/Hyperactivity Disorder: Statistical Significance is Necessary, but is it Sufficient? Psychopharmacology Bulletin 37:50-58, 2003.
27. Sangal JM, Sangal RB. Attention-Deficit/Hyperactivity Disorder: Cognitive Evoked Potential (P300) Topography Predicts Treatment Response to Methylphenidate. Clin Neurophysiology, 115:188-193, 2004.
28. Sangal RB, Sangal JM. Rating Scales for Inattention and Sleepiness are Correlated in Adults with symptoms of Sleep Disordered Breathing Syndrome, but not in Adults with symptoms of Attention-Deficit/Hyperactivity Disorder. Sleep Med, 5:133-135, 2004.
29. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. A Double-Blind, Placebo-Controlled Trial of Dexmethylphenidate Hydrochloride and d,l-threo- Methylphenidate Hydrochloride in children with Attention Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiat, 43:1406-1414, 2004.
30. Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, Scott RA, Sangal RB, Bohan TP, Zeldis JB. A Double-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children With Attention Deficit Hyperactivity Disorder. J Child Adolesc Psychopharm, 14:542-554, 2004.
31. Sangal JM, Sangal RB. Attention-Deficit/Hyperactivity Disorder: Cognitive Evoked Potential (P300) Amplitude Predicts Treatment Response to Atomoxetine. Clin Neurophysiology, 116:640-647, 2005.
32. Sangal RB, Owens J, Sangal JM. Patients With Attention-Deficit/Hyperactivity Disorder Without Observed Apneic Episodes in Sleep or Daytime Sleepiness Have Normal Sleep on Polysomnography. Sleep, 28:1143-1147, 2005.
33. Greenhill LL, Beiderman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, Jiang JG, Swanson JM. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Adolesc Psychiatry, 45:503-511, 2006.
34. Sangal RB, Sangal JM. Attention-Deficit/Hyperactivity Disorder: Use of Cognitive Evoked Potential (P300) To Predict Treatment Response. Clin Neurophysiology, 117:1996-2006, 2006.
35. Sangal RB, Sangal JM. Attention-Deficit/Hyperactivity Disorder: Using P300 topography to choose optimal treatment. Expert Review of Neurotherapeutics, 10:1429-1437, 2006.
36. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol, 6:648-652, 2006.
37. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ, for the Atomoxetine low-dose study group (incl. Sangal RB). Low-Dose Atomoxetine for Maintenance treatment of Attention-Deficit/Hyperactivity Disorder. Pediatrics, 118:e1701-e1706, 2006.
38. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of Atomoxetine and Methylphenidate on Sleep in Children with ADHD. Sleep, 29:1573-1585, 2006.
39. Spencer T, Kratochvil C, Sangal RB, Saylor K, Bailey C, Dunn D, Geller D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Furr A, Allen AJ. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol, 17:689-699, 2007.
40. Vanhecke TE, Franklin BA, Ajluni SC, Sangal RB, McCullough PA. Cardiorespiratory fitness and sleep-related breathing disorders. Expert Rev Cardiovasc Ther, 6:745-758, 2008.
41. Sangal RB, Owens J, Sangal JM. Atomoxetine improves Sleepiness and Global Severity of Illness but not the Respiratory Disturbance Index in Mild to Moderate Obstructive Sleep Apnea with Sleepiness. Sleep Medicine, 9:506-510, 2008.
42. Vanhecke TE, Franklin BA, Zalesin KC, Sangal RB, deJong AD, Agrawal V, et al. Cardiorespiratory Fitness and Obstructive Sleep Apnea Syndrome in Morbidly Obese Patients. Chest,134:539-545, 2008.
43. Owens J, Sangal RB, Sutton VK, Bakken R, Allen AA, Kelsey D. Subjective and Objective Measures of Sleep in children with Attention-Deficit/Hyperactivity Disorder. Sleep Medicine, 10:446-456, 2009.
44. Agrawal V, Vanhecke TE, Rai B, Franklin BA, Sangal RB, McCullough PA. Albuminuria and Renal Function in Obese Adults Evaluated for Obstructive Sleep Apnea. Nephron Clin Pract, 113:c140-c147, 2009.
45. Soriano-Co M, Vanhecke TE, Franklin BA, Sangal RB, Hakmeh B, McCullough PA. Increased central adiposity in morbidly obese patients with obstructive sleep apnea. Intern Med J, 33:21-37, 2011.
46. Bain EE, Apostol G, Sangal RB, Robieson WZ, McNeill D, Abi-Saab WA, Saltarelli MD. A randomized pilot study of the efficacy and safety of ABT-089, a novel a4b2 neuronal nicotinic receptor agonist, in adults with attention-deficit hyperactivity disorder. J Clinical Psychiatry, 73:783-789, 2012.
47. Sangal RB. Evaluating Sleepiness-Related Daytime Function by Querying Wake Inability and Fatigue: SWIFT (Sleepiness-Wakefulness Inability and Fatigue Test). J Clin Sleep Med, 8:701-711, 2012.
48. Sangal RB, Blumer J, Lankford A, Grinnell T, Huang H. Eszopiclone for Insomnia associated with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 134:e1095-1103, 2014.
49. Sangal RB, Sangal JM. Use of EEG Beta-1 Power and Theta/Beta Ratio over Broca’s Area to confirm diagnosis of Attention Deficit/Hyperactivity Disorder in Children. Clin EEG Neurosci, 46:177-182, 2015.
50. Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D. Suvorexant in patients with Insomnia: Results from two 3-month Randomized Controlled Clinical Trials. Biol Psychiatry, 79:136-148, 2016.
51. Sangal RB. Baseline sleep efficiency and arousal index do not predict who will benefit from sedatives in improving Positive Airway Pressure Ahderence in sleep apnea to 90%. Clin EEG Neurosci, 49:285-289, 2018.
52. Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled tiral. Am J Respir Crit Care Med, 199:1421-1431, 2019.
53. Sangal RB, Sudan N. Baseline lighter sleep and lower saturation are associated with improved sleepiness and adherence on continuous rather than autotitrating positive airway pressure. Clin EEG Neurosci, 51:174-179, 2020.
54. Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. The combination of aroxybutynin and atomoxetine in the treatment of obstructive sleep apnea (MARIPOSA): A randomized controlled trial. Am J Respir Crit Care Med, 15:208(12):1316-1327, 2023.

Case Reports:

1. Sangal, R. Inhibited Female Orgasm as a Side-Effect of Alprazolam. Am. J. Psychiatry, 142:1223-1224, 1985.

Review Articles:

1. Chesson AL, Ferber RA, Fry JM, Grigg-Damberger M, Hartse KM, Hurwitz TD, Johnson S, Kader GA, Littner M, Rosen G, Sangal RB, Schmidt-Nowara W, Sher A. The Indications for Polysomnography and Related Procedures. Sleep, 20:423-487, 1997.
2. Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB. The clinical use of the MSLT and MWT. Sleep, 123-144, 2005.
3. Sangal RB, Sangal JM. Attention-Deficit/Hyperactivity Disorder: Using P300 Topography to Choose Optimal Treatment. Expert Rev Neurother, 6:1429-1437, 2006.

Abstracts (last five years) as first author which have not yet been reported in a peer-reviewed publication:

There are numerous abstracts as middle author, abstracts more than five years old, and abstracts with content that has since been published as a peer reviewed publication, and these are not being listed.

Editorials/Commentaries:

1. Sangal R. Medical Profession and the Population Problem in the Student as Future Physician Perspective. The Indian Journal of Medical Education, 13:185-186, 1974.
2. Sangal R. Electroconvulsive Treatment: A Rose is a Rose (Editorial). Biological Psychiatry, 21:709, 1986.
3. Sangal RB. Conclusions from Brain Mapping: Need for Statistical Rigor (Guest Editorial). Clinical Electroencephalography, 29:V, 1998.
4. Sangal RB. When is Sleepiness a Disease? How do we Measure It? Sleep Medicine, 7:310-311, 2006.
5. Sangal RB. Auto-titrating CPAP for the treatment of obstructive sleep apnea in children: APAP and CPAP pressures were not that close. (Letter to Editor) J Clin Sleep Med, 16:1823, 2020.
6. Sangal RB. Efficacy and safety of esmirtazapine in adult insomnia: unsupported statements about residual daytime effects. (Letter to Editor) J Clin Sleep Med, 17:341, 2021.

• Peer-Reviewed Medical Publications
• Clinical Trials & Activities
• Curriculum Vitae